Wei Jiang
Novartis
2 Papers
Wei Jiang is an academic researcher from Novartis. The author has contributed to research in topics: Warburg effect & Cancer. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Phosphoglycerate dehydrogenase is dispensable for breast tumor maintenance and growth.
Jinyun Chen,Franklin Chung,Guizhi Yang,Minying Pu,Hui Gao,Wei Jiang,Hong Yin,Vladimir Capka,Shailaja Kasibhatla,Bryan Laffitte,Savina Jaeger,Raymond Pagliarini,Yaoyu Chen,Wenlai Zhou +13 more
TL;DR: It is reported that PHDGH is overexpressed in many ER-negative human breast cancer cell lines, indicating that PHGDH is dispensable for the growth and maintenance of tumors in vivo.
Isocitrate Dehydrogenase (IDH) Mutations Promote a Reversible ZEB1/MicroRNA (miR)-200-dependent Epithelial-Mesenchymal Transition (EMT) *
Alexandra R. Grassian,Fallon Lin,Rosemary Barrett,Yue Liu,Wei Jiang,Manav Korpal,Holly Astley,D P Gitterman,Thomas Henley,Rob Howes,Julian Levell,Joshua M. Korn,Raymond Pagliarini +12 more
TL;DR: In this article, the effect of IDH mutations on 2-hydroxyglutarate (2-HG) was examined in a panel of isogenic epithelial cell lines with either wild-type IDH 1/2 or clinically relevant IDH1/2 mutations.